Glucocorticoids are a cornerstone in the treatment of multiple myeloma, a plasma cell malignancy located in the bone marrow. Prolonged treatment with glucocorticoids leads to GC resistance. We aim to establish novel mechanistic insights in GC resistance development by studying the link between the onset of GC resistance and a dysfunctional GR signaling pathway.